Table 1.
Tumor pathology and molecular characteristics
| Characteristic | Total (n = 80), n (%) | Response to ICIsa | PFSHR (95% CI), p valueb | OSHR (95% CI), p valueb | ||
|---|---|---|---|---|---|---|
| CR and PR (n = 48), n (%) | SD and PD (n = 31), n (%) | p valueb | ||||
| Primary tumor location | ||||||
| a. Right | 56 (70.0) | 32 (66.7) | 24 (77.4) | .187 |
1.07 (0.44–2.62), .882 |
0.68 (0.27–1.72), .410 |
| b. Left / Rectum | 22 (27.5) | 16 (33.3) | 5 (16.1) | |||
| Missing | 2 (2.5) | 2 (6.5) | ||||
| Mucinous histology | ||||||
| a. Yes | 36 (45.0) | 18 (37.5) | 18 (58.1) | .105 |
2.17 (0.95–4.96), .067 |
1.41 (0.58–3.47), .458 |
| b. No | 44 (55.0) | 30 (62.5) | 13 (41.9) | |||
| Lymphovascular invasion | ||||||
| a. Yes | 44 (55.0) | 30 (62.5) | 14 (45.2) | .3383 |
0.43 (0.16–1.17), .099 |
0.41 (0.14–1.19), .100 |
| b. No | 15 (18.8) | 7 (14.6) | 7 (22.6) | |||
| Missing | 21 (26.2) | 11 (22.9) | 10 (32.2) | |||
| Grading | ||||||
| a. High grade | 67 (83.7) | 39 (81.3) | 27 (87.1) | .5517 |
2.48 (0.58–10.63), .222 |
1.80 (0.42–7.84), .430 |
| b. Low grade | 13 (16.3) | 9 (18.7) | 4 (12.9) | |||
| RAS mutation | ||||||
| a. Mutation | 27 (32.5) | 17 (33.3) | 9 (29.0) | .8059 |
0.98 (0.41–2.33), .967 |
1.34 (0.56–3.48), .474 |
| b. WT | 53 (67.5) | 31 (66.7) | 22 (71.0) | |||
| BRAF mutation | ||||||
| a. Mutation | 28 (35.0) | 16 (33.3) | 12 (38.7) | .6386 |
1.26 (0.55–2.91), .588 |
1.52 (0.61–3.78), .369 |
| b. WT | 52 (65.0) | 32 (66.7) | 19 (61.3) | |||
| Number of TILs | ||||||
| a. High | 52 (65.0) | 36 (75.0) | 15 (48.4) | .029 |
0.42 (0.15–0.88), .028 |
0.41 (0.14–0.98), .046 |
| b. Low | 28 (35.0) | 12 (25.0) | 16 (51.6) | |||
One patient not evaluable for response to ICIs.
All comparisons made for variable a versus b. Fisher's exact test was adopted for response analyses, log‐rank test for PFS and OS analyses. Significant p values in bold.
Abbreviations: CI, confidence interval; CR, complete response; HR, hazard ratio; ICI, immune checkpoint inhibititor; PD, progressive disease; PFS, progression‐free survival; PR, partial response; SD, stable disease; TIL, tumor infiltrating lymphocyte; WT, wild type.